Patient engagement and study design of PROP UP

A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment

Donna M. Evon, Carol E. Golin, Paul Stewart, Michael W. Fried, Shani Alston, Bryce Reeve, Anna S. Lok, Richard K. Sterling, Joseph K. Lim, Nancy Reau, Souvik Sarkar, David R. Nelson, K. R. Reddy, Adrian M. Di Bisceglie

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background New highly efficacious direct-acting antiviral (DAA) therapies are available to treat chronic hepatitis C viral (HCV) infection. Real-world, patient-centered data on harms and benefits associated with these therapies are needed. Methods PROP UP is a multi-center prospective observational study that plans to enroll 1600 patients starting treatment with recently-approved DAA regimens. Informed by extensive input from a HCV patient engagement group who prioritized outcomes most important to them, patient-reported outcomes will be characterized using surveys at five time points: Baseline (T1), treatment week 4 (T2), end of treatment (T3), 12 weeks post-treatment (T4), 12 months post-treatment (T5). Outcomes (1) Changes in side effects, functioning, pre-existing conditions, and out-of-pocket costs during therapy (T1 vs T2/T3); (2) Medication adherence in relation to a history of mental health/substance abuse, treatment regimens, pill burden, reasons for missed doses, and cure rates; (3) Short term impact of cure on functioning and amelioration of symptoms (T1 vs T4); (4) Long-term treatment harms or benefits of cure on symptoms, side effects, pre-existing conditions, and functioning (T1 vs T5). Similarities between regimens will be examined where comparisons are appropriate and meaningful. Conclusion PROP UP complements previous clinical trials by focusing on patient-reported outcomes in a representative sample of patients treated in clinical practice, by collaborating with a patient engagement group, by characterizing the experiences of vulnerable subgroups, and by investigating long-term harms and benefits of treatments. PROP UP is designed to provide novel and detailed information to support informed decision-making for patients and providers contemplating HCV treatment (PCORI CER-1408-20,660; NCT02601820).

Original languageEnglish (US)
Pages (from-to)58-68
Number of pages11
JournalContemporary Clinical Trials
Volume57
DOIs
StatePublished - Jun 1 2017

Fingerprint

Patient Participation
Hepatitis C
Observational Studies
Prospective Studies
Therapeutics
Preexisting Condition Coverage
Antiviral Agents
Patient Advocacy
Medication Adherence
Chronic Hepatitis C
Virus Diseases
Health Expenditures
Substance-Related Disorders
Decision Making
Mental Health

Keywords

  • Direct acting antiviral (DAA)
  • Hepatitis
  • Liver
  • Patient-centered outcomes research (PCOR)
  • Patient-reported outcomes

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Patient engagement and study design of PROP UP : A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. / Evon, Donna M.; Golin, Carol E.; Stewart, Paul; Fried, Michael W.; Alston, Shani; Reeve, Bryce; Lok, Anna S.; Sterling, Richard K.; Lim, Joseph K.; Reau, Nancy; Sarkar, Souvik; Nelson, David R.; Reddy, K. R.; Di Bisceglie, Adrian M.

In: Contemporary Clinical Trials, Vol. 57, 01.06.2017, p. 58-68.

Research output: Contribution to journalArticle

Evon, DM, Golin, CE, Stewart, P, Fried, MW, Alston, S, Reeve, B, Lok, AS, Sterling, RK, Lim, JK, Reau, N, Sarkar, S, Nelson, DR, Reddy, KR & Di Bisceglie, AM 2017, 'Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment', Contemporary Clinical Trials, vol. 57, pp. 58-68. https://doi.org/10.1016/j.cct.2017.03.013
Evon, Donna M. ; Golin, Carol E. ; Stewart, Paul ; Fried, Michael W. ; Alston, Shani ; Reeve, Bryce ; Lok, Anna S. ; Sterling, Richard K. ; Lim, Joseph K. ; Reau, Nancy ; Sarkar, Souvik ; Nelson, David R. ; Reddy, K. R. ; Di Bisceglie, Adrian M. / Patient engagement and study design of PROP UP : A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. In: Contemporary Clinical Trials. 2017 ; Vol. 57. pp. 58-68.
@article{3a85d56b0e3b402d9c869940e7a673a8,
title = "Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment",
abstract = "Background New highly efficacious direct-acting antiviral (DAA) therapies are available to treat chronic hepatitis C viral (HCV) infection. Real-world, patient-centered data on harms and benefits associated with these therapies are needed. Methods PROP UP is a multi-center prospective observational study that plans to enroll 1600 patients starting treatment with recently-approved DAA regimens. Informed by extensive input from a HCV patient engagement group who prioritized outcomes most important to them, patient-reported outcomes will be characterized using surveys at five time points: Baseline (T1), treatment week 4 (T2), end of treatment (T3), 12 weeks post-treatment (T4), 12 months post-treatment (T5). Outcomes (1) Changes in side effects, functioning, pre-existing conditions, and out-of-pocket costs during therapy (T1 vs T2/T3); (2) Medication adherence in relation to a history of mental health/substance abuse, treatment regimens, pill burden, reasons for missed doses, and cure rates; (3) Short term impact of cure on functioning and amelioration of symptoms (T1 vs T4); (4) Long-term treatment harms or benefits of cure on symptoms, side effects, pre-existing conditions, and functioning (T1 vs T5). Similarities between regimens will be examined where comparisons are appropriate and meaningful. Conclusion PROP UP complements previous clinical trials by focusing on patient-reported outcomes in a representative sample of patients treated in clinical practice, by collaborating with a patient engagement group, by characterizing the experiences of vulnerable subgroups, and by investigating long-term harms and benefits of treatments. PROP UP is designed to provide novel and detailed information to support informed decision-making for patients and providers contemplating HCV treatment (PCORI CER-1408-20,660; NCT02601820).",
keywords = "Direct acting antiviral (DAA), Hepatitis, Liver, Patient-centered outcomes research (PCOR), Patient-reported outcomes",
author = "Evon, {Donna M.} and Golin, {Carol E.} and Paul Stewart and Fried, {Michael W.} and Shani Alston and Bryce Reeve and Lok, {Anna S.} and Sterling, {Richard K.} and Lim, {Joseph K.} and Nancy Reau and Souvik Sarkar and Nelson, {David R.} and Reddy, {K. R.} and {Di Bisceglie}, {Adrian M.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.cct.2017.03.013",
language = "English (US)",
volume = "57",
pages = "58--68",
journal = "Contemporary Clinical Trials",
issn = "1551-7144",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Patient engagement and study design of PROP UP

T2 - A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment

AU - Evon, Donna M.

AU - Golin, Carol E.

AU - Stewart, Paul

AU - Fried, Michael W.

AU - Alston, Shani

AU - Reeve, Bryce

AU - Lok, Anna S.

AU - Sterling, Richard K.

AU - Lim, Joseph K.

AU - Reau, Nancy

AU - Sarkar, Souvik

AU - Nelson, David R.

AU - Reddy, K. R.

AU - Di Bisceglie, Adrian M.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Background New highly efficacious direct-acting antiviral (DAA) therapies are available to treat chronic hepatitis C viral (HCV) infection. Real-world, patient-centered data on harms and benefits associated with these therapies are needed. Methods PROP UP is a multi-center prospective observational study that plans to enroll 1600 patients starting treatment with recently-approved DAA regimens. Informed by extensive input from a HCV patient engagement group who prioritized outcomes most important to them, patient-reported outcomes will be characterized using surveys at five time points: Baseline (T1), treatment week 4 (T2), end of treatment (T3), 12 weeks post-treatment (T4), 12 months post-treatment (T5). Outcomes (1) Changes in side effects, functioning, pre-existing conditions, and out-of-pocket costs during therapy (T1 vs T2/T3); (2) Medication adherence in relation to a history of mental health/substance abuse, treatment regimens, pill burden, reasons for missed doses, and cure rates; (3) Short term impact of cure on functioning and amelioration of symptoms (T1 vs T4); (4) Long-term treatment harms or benefits of cure on symptoms, side effects, pre-existing conditions, and functioning (T1 vs T5). Similarities between regimens will be examined where comparisons are appropriate and meaningful. Conclusion PROP UP complements previous clinical trials by focusing on patient-reported outcomes in a representative sample of patients treated in clinical practice, by collaborating with a patient engagement group, by characterizing the experiences of vulnerable subgroups, and by investigating long-term harms and benefits of treatments. PROP UP is designed to provide novel and detailed information to support informed decision-making for patients and providers contemplating HCV treatment (PCORI CER-1408-20,660; NCT02601820).

AB - Background New highly efficacious direct-acting antiviral (DAA) therapies are available to treat chronic hepatitis C viral (HCV) infection. Real-world, patient-centered data on harms and benefits associated with these therapies are needed. Methods PROP UP is a multi-center prospective observational study that plans to enroll 1600 patients starting treatment with recently-approved DAA regimens. Informed by extensive input from a HCV patient engagement group who prioritized outcomes most important to them, patient-reported outcomes will be characterized using surveys at five time points: Baseline (T1), treatment week 4 (T2), end of treatment (T3), 12 weeks post-treatment (T4), 12 months post-treatment (T5). Outcomes (1) Changes in side effects, functioning, pre-existing conditions, and out-of-pocket costs during therapy (T1 vs T2/T3); (2) Medication adherence in relation to a history of mental health/substance abuse, treatment regimens, pill burden, reasons for missed doses, and cure rates; (3) Short term impact of cure on functioning and amelioration of symptoms (T1 vs T4); (4) Long-term treatment harms or benefits of cure on symptoms, side effects, pre-existing conditions, and functioning (T1 vs T5). Similarities between regimens will be examined where comparisons are appropriate and meaningful. Conclusion PROP UP complements previous clinical trials by focusing on patient-reported outcomes in a representative sample of patients treated in clinical practice, by collaborating with a patient engagement group, by characterizing the experiences of vulnerable subgroups, and by investigating long-term harms and benefits of treatments. PROP UP is designed to provide novel and detailed information to support informed decision-making for patients and providers contemplating HCV treatment (PCORI CER-1408-20,660; NCT02601820).

KW - Direct acting antiviral (DAA)

KW - Hepatitis

KW - Liver

KW - Patient-centered outcomes research (PCOR)

KW - Patient-reported outcomes

UR - http://www.scopus.com/inward/record.url?scp=85018486909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018486909&partnerID=8YFLogxK

U2 - 10.1016/j.cct.2017.03.013

DO - 10.1016/j.cct.2017.03.013

M3 - Article

VL - 57

SP - 58

EP - 68

JO - Contemporary Clinical Trials

JF - Contemporary Clinical Trials

SN - 1551-7144

ER -